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Abstract
Introduction: Parathyroid hormone (PTH) might be considered as a potential marker of disease severity and worse prognosis in heart 
failure (HF) patients. 
The aim of the study was to assess PTH, vitamin D, phosphorus (P), and total calcium (Ca2+) serum concentrations in Central European 
patients suffering from HF of non-ischaemic origin compared to non-HF volunteers.To evaluate potential correlations among the enumer-
ated parameters, established markers of worse prognosis and declared sun exposure. 
Material and methods: Serum intact-PTH, 25-OH vitamin D, P, and total Ca2+ concentrations were assessed in a group of HF patients 
and non-HF volunteers. Patients described their daily profile of sun exposure during the previous eight weeks as “above” or “below” 
seven hours a week.
Results: The mean PTH concentrations in the non-ischaemic HF group and control group were 79.5 pg/mL and 59.6 pg/mL, respectively 
(P = 0.009). Non-HF volunteers declaring higher sun exposure time had higher serum concentrations of vitamin D compared to those with 
lower sun exposure time (30.3 vs. 23.8 ng/mL, P < 0.05), unlike the HF patients (24.1 ng/mL vs. 23.2 ng/mL, P = ns). Multiple regression 
analysis revealed the relationship between age, NT-proBNP (N-terminal pro-brain natriuretic peptide), P, and PTH as a dependent variable.
Conclusions: PTH is significantly elevated in non-ischaemic HF patients compared to non-HF volunteers and correlates with established 
factors of worse prognosis, including age, estimated glomerular filtration rate (eGFR), aspartate aminotransferase (AST), serum con-
centrations of creatinine, and NT-proBNP. Declared sun exposure did not affect the serum concentration of vitamin D in the HF group, 
in contrast to the control group. (Endokrynol Pol 2017; 68 (3): 299–305)
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Streszczenie
Wstęp: Podwyższone stężenie parathormonu (PTH) jest uważane za potencjalny marker ciężkości choroby i złego rokowania u chorych 
z niewydolnością serca (NS).
Celem pracy była ocena stężenia PTH, witaminy D, całkowitego wapnia (Ca2+) i fosforu (P) w surowicy krwi środkowoeuropejskich 
chorych z nie-niedokrwienną NS w porównaniu z grupą bez NS. Określenie potencjalnych zależności wymienionych parametrów 
z ustalonymi markerami złego rokowania oraz deklarowanym czasem ekspozycji na słońce.
Materiał i metody: W obu grupach oznaczono stężenie aktywnego biologicznie PTH, 25-OH witaminy D, Ca2+ i P. Pacjenci deklarowali 
czas ekspozycji na słońce w ciągu ostatnich ośmiu tygodni jako „powyżej” lub „poniżej” siedmiu godzin w tygodniu.
Wyniki: Średnie stężenie PTH było wyższe w grupie badanej (79,5 vs. 59,6 pg/ml, p = 0,009). W grupie bez niewydolności serca u osób 
deklarujących czas ekspozycji na słońce > 7h/tygodniu obserwowano wyższe stężenie witaminy D (30,3 vs. 23,8 ng/ml, p < 0,05), zależność 
ta nie zachodziła u pacjentów z NS (24,1 ng/ml vs. 23,2 ng/ml, p = ns). Analiza regresji wieloczynnikowej wykazała zależność między 
wiekiem, stężeniem N-końcowego fragmentu prohormonu peptydu natriuretycznego (NT-proBNP), P oraz PTH jako zmienną zależną.
Wnioski: Stężenie PTH jest wyższe w grupie pacjentów z nie-niedokrwienną NS w porównaniu z ochotnikami bez NS. Stężenie PTH 
koreluje z ustalonymi czynnikami złego rokowania jak wiek, estymowany wskaźnik filtracji kłębkowej (eGFR), stężenie kreatyniny, 
aminotransferazy asparaginianowej oraz NT-proBNP. W przeciwieństwie do grupy kontrolnej, deklarowana ekspozycja na słońce nie 
wpływa na stężenie witaminy D u pacjentów z NS. (Endokrynol Pol 2017; 68 (3): 299–305)
Słowa kluczowe: kardiomiopatia rozstrzeniowa; niewydolność serca; N-końcowy fragment prohormonu peptydu natriuretycznego; 
parathormon; witamina D
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Abbreviations
ALT — alanine transferase
AST — aspartate aminotransferase
CKD — chronic kidney disease
CAD — coronary artery disease
DCM — dilated cardiomyopathy
eGFR — estimated glomerular filtration rate
ESC — European Society of Cardiology
HF — heart failure
MDRD — Modification of Diet in Renal Disease
NT-proBNP — N-terminal pro-brain natriuretic peptide
PTH — parathyroid hormone
P — phosphorus
SD — standard deviation
Ca2+ — total calcium
Introduction
It is estimated that 1–2% of the population in devel-
oped countries suffers from heart failure (HF), and 
half of these cases are associated with impaired left 
ventricle contractility mainly due to coronary artery 
disease (CAD) or hypertension [1]. Patients with heart 
failure caused by dilated cardiomyopathy (DCM) of 
non-ischaemic origin remain an interesting observa-
tional group in whom the relationship between the 
serum concentration of parathyroid hormone (PTH) 
and other biochemical and clinical parameters was not 
fully elucidated. PTH is a polypeptide that is produced 
in the structure of the parathyroid gland in response 
to the diminution of calcium ions (Ca2+) in the extra-
cellular fluid. Its secretion is based on the principle of 
a negative feedback loop with the serum concentration 
of physiologically active Ca2+ ions. PTH increases the 
serum concentration of ionised Ca2+ due to an enhance-
ment of its reabsorption in renal tubules and increase 
in phosphate secretion and osteoclast activation [2]. 
On the basis of the regulation of alpha-1 hydroxyla-
tion of 25-OH vitamin D, it has a crucial effect on the 
absorption of Ca2+ in the intestinal tract [3]. PTH has 
a significant effect on the cardiovascular system via its 
widespread receptors in the myocardium, endothelial, 
and smooth muscle cells. Its biologically active form, 
known as intact PTH, is secreted by the parathyroid 
gland and consists of eighty-four amino acids. PTH 
resolves into two components – active N-terminal PTH 
and inactive C-terminal PTH, which is excreted via the 
renal route. The active PTH forms (84-PTH and N-PTH) 
are mainly metabolised in the liver, resulting in a short 
half-life of intact PTH, which is relatively independent 
of renal function, although its serum concentration cor-
relates with the absolute amount of the hormone and its 
activity [3,4]. The PTH serum concentration is increased 
in primary hyperparathyroidism, vitamin D deficiency, 
or chronic kidney disease (CKD). Augmentation of PTH 
serum concentration in HF patients has a potential 
negative effect on symptom severity and prognosis. 
Material and methods
The aim of this study was to assess the serum concentra-
tions of PTH, total calcium (Ca2+), P, and vitamin D in 65 
consecutive patients with non-ischaemic heart failure, 
who were hospitalised in our centre from March 1, 2012 
to September 15, 2014. The control group consisted 
of sixty-two non-HF volunteers. Exclusion criteria in 
both groups were: CKD stage four or higher, vitamin 
D supplementation, diagnosed primary hyperpar-
athyroidism, or malignancy. The blood samples of the 
HF patients enrolled in the study were collected on 
admission. The study complies with the Declaration of 
Helsinki, was approved by the local ethics committee 
(number of approval KNW/0022/KB1/40/I/12/13), and 
all patients provided informed consent.
Serum intact-PTH concentration was assessed 
in both groups using the immunoradiometric assay 
technique with the DIAsource hPTH-120 min-IRMA 
Kit (DIAsource Immunoassays S.A., Belgium). The vi-
tamin D serum concentration was assessed using the 
radioimmunoassay with the DIAsource 25-OH vitamin 
D total-RIA-CT Kit (DIAsource Immunoassays S.A., 
Belgium). Serum P and total Ca2+ concentrations were 
assessed using the enzymatic method as described by 
Spinreact S.A., Spain and the colorimetric Arsenazo III 
method as described by Biomaxima S.A., Poland. In the 
HF patients, routine examinations were performed on 
admission according to the guidelines of the European 
Society of Cardiology (ESC), which consisted of peri-
pheral blood morphology, creatinine, aspartate (AST), 
and alanine (ALT) transferases and N-terminal pro-
brain natriuretic peptide (NT-proBNP) serum concen-
trations. The estimated glomerular filtration rate (eGFR) 
was calculated on the basis of the Modification of Diet 
in Renal Disease (MDRD) formula. The New York Heart 
Association (NYHA) functional class assessment and 
echocardiography examination were performed upon 
admission to the hospital. Left ventricular systolic func-
tion impairment was caused by dilated cardiomyopathy 
in the majority of cases (60 patients — 92.3% of cases), 
which were mostly postinflammatory, idiopathic, or, in 
one female, postpartum in origin. All patients were sub-
jected to invasive coronary angiography to exclude the 
ischaemic background of HF. Patients were requested to 
characterise their daily profile of sun exposure during 
the last eight weeks as “above” or “below” seven hours 
a week, equivalent to one hour per day. Importantly, the 
population of Poland, which has approximately forty 
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million people, exhibits a temperate climate in Central 
Europe, and its inhabitants frequently suffer from 
vitamin D deficiency due to insufficient sun exposure 
and nutritional supply. 
Statistical analysis
The distributions of the examined parameters were 
analysed using the Shapiro-Wilk test. Values were pre-
sented as the mean and standard deviation (SD) or as 
the median in the 25th and 75th percentiles. Nominal 
and categorical values were expressed in percentages 
or proportional rates. Linear variables with normal 
distribution were compared using Student’s t-test. 
Variables with abnormal distribution were compared 
using the Kolmogorov-Smirnov, Mann-Whitney U, and 
Kruskall-Wallis tests. Categorical variables of abnormal 
distribution were compared using Chi-square test with 
Yates correction or Fischer ’s exact test. Quantified 
Spearman’s rho correlation coefficients were used to as-
sess the linear correlations between variables. Multiple 
regression analysis with PTH as a dependent variable 
led to a construction of two PTH serum concentra-
tion models. The basic model consisted of arbitrarily 
included parameters while the secondary model was 
constructed on the base of the backward stepwise 
method. Differences between the values were medical 
package (Statsoft Inc.).
Results
The heart failure group (65 participants) and the control 
group (62 participants) did not differ in age (51.6 vs. 53.8, 
P = ns) and gender (males 80% and 70%, respectively, 
P = ns). Group characteristics are presented in Table I.
The mean PTH concentration in the non-ischaemic 
HF group was 79.5 pg/mL, and the range was 3.9–198.8 
pg/mL, SD 46.4 pg/mL. In the control group, the mean 
PTH concentration was 59.6 pg/mL, and the range was 
18.3–124.8 pg/mL, SD 23.8 pg/mL. The mean values of 
serum PTH concentrations were significantly higher in 
the heart failure group (P = 0.009) (Fig. 1).
The mean PTH values in specific groups of patients di-
vided according to the NYHA functional class were as fol-
lows: NYHA I (mean 58.8 pg/mL, range 6.8–77.5 pg/mL), 
Table I. Group characteristics
Tabela I. Charakterystyka grupy
HF 
n = 65 (%)
Non-HF volunteers 
n = 62 (%)
P
Age 51.6 [42–60] 53.8 [42–64] ns
Males 53 (80) 45 (70) ns
Arterial hypertension 32 (49) 33 (53) ns
Diabetes 17 (26) 13 (21) ns
Coronary artery disease 0 (0) 27 (43) P < 0.0001 
Vitamin D concentration < 30 [ng/mL] 47 (72) 35 (56) P = 0.046
Egfr < 60, ml/min/1.73 m2 9 (14) 0 (0) P = 0.007
Sun exposure > 7 h/week 12 (20) 41 (70) P < 0.0001
Icd/crt 38 (58) 0 (0) P < 0.0001
Eligible for cardiac transplantation 16 (25) 0 (0) P < 0.0001
Atrial fibrillation 21 (32) 2 (3) P < 0.0001
Left bundle branch block 23 (35) 0 (0) P < 0.0001
Ace-i 65 (100) 29 (46) P < 0.0001 
Beta blockers 63 (97) 28 (45) P < 0.0001 
Diuretics 57 (88) 13 (21) P < 0.0001 
LVEF, % 24.5 55.1 P < 0.001
NYHA I 4 (6) –
NYHA II 38 (58) –
NYHA III 16 (25) –
NYHA IV 7 (11) –
Data are presented as mean and percentage. ACE-I — angiotensin converting enzyme inhibitors; eGFR — estimated glomerular filtration rate; HF — heart failure;  
ICD/CRT — implantable cardioverter defibrillator/cardiac resynchronisation therapy; LVEF — left ventricular ejection fraction; NYHA — New York Heart Association
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NYHA II (mean 74.4 pg/mL, range 3.9–198.8 pg/mL), 
NYHA III (mean 87.0 pg/mL, range 8.3–168.3 pg/mL), and 
NYHA IV (mean 101.2 pg/mL, range 47.3–162.8 pg/mL), 
which trended towards statistical significance 
(P = 0.082) (Fig. 2). 
The mean Vitamin D concentration was significantly 
lower in the HF group (23.4 ng/mL vs. 28.1 ng/mL, 
P = 0,006), although in both groups the mean concen-
tration was below optimal range (30 ng/mL). In our 
group Vitamin D deficiency was not significantly cor-
related to the disease severity (NYHA class) nor another 
assessed marker of poor prognosis.
Patients with HF, who declared a sun exposure time 
greater than seven hours a week, had significantly 
higher serum Ca2+ concentrations (10.0 vs. 9.5 ng/mL, 
P < 0.025) and were significantly younger (43.6 vs. 53.4 
years, P < 0.01) compared to those who declared the 
lesser sun exposure values. Differences between other 
analysed parameters (PTH, P, vitamin D) were statisti-
cally insignificant. Non-HF volunteers declaring a sun 
exposure time greater than seven hours a week had 
higher serum concentrations of vitamin D than those 
with lower values (30.3 vs. 23.8 ng/mL, P < 0.05), unlike 
the HF patients (24.1 ng/mL vs. 23.2 ng/mL, P = ns). 
Differences among other values (PTH, P, Ca2+) were 
statistically insignificant (Table II).
The Spearmann coefficient analysis revealed a sta-
tistically significant correlation between the serum con-
centration of PTH in HF patients and established factors 
of worse prognosis, such as age (r = 0.26, P = 0.035), cre-
atinine concentration (r = 0.26, P = 0.037), AST (r = 0.32, 
P = 0.009), NT-proBNP (r = 0.37, P = 0.003), and eGFR 
(r = –0.36, P = 0.003). Moreover, statistically significant 
correlations were observed between PTH and Ca2+ 
(r = –0.29, P = 0.02) and PTH and P (r = –0.35, 
P = 0.004). A correlation between PTH and haemoglobin 
Figure 1. Parathyroid hormone serum concentration in heart 
failure patients vs. non-heart failure volunteers
Rycina 1. Stężenie parathormonu w surowicy krwi u chorych z 
niewydolnością serca wobec osób bez niewydolności serca
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Figure 2. Parathyroid hormone serum concentration according 
to New York Heart Association class
Rycina 2. Stężenie parathormonu w surowicy krwi zależnie 
od klasy czynnościowej zgodnie z klasyfikacją Nowojorskiego 
Towarzystwa Kardiologicznego 
p = 0.082
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Table II. Impact of sun exposure on the examined parameters
Tabela II. Wpływ ekspozycji na słońce na badane parametry
HF (n = 65) non-HF volunteers (n = 62)
SE > 7 h/week (n = 12) SE < 7 h/week (n = 53) P SE > 7 h/week (n = 41) SE < 7 h/week (n = 21) P
Mean SD Mean SD Mean SD Mean SD
PTH [pg/mL] 73.0 30.1 80.9 49.5 ns 59.9 26.1 59.0 19.2 ns
Ca2+ [mg/dL] 10.0 0.4 9.5 0.6  < 0.025 9.6 0.4 9.6 0.6 ns
P [mmol/L] 1.2 0.2 1.2 0.2 ns 1.3 0.2 1.3 0.2 ns
Vit. D [ng/mL] 24.1 8.3 23.2 13.9 ns 30.3 11.1 23.8 10.8 < 0.05
Age (years) 43.6 10.9 53.4 12.0  < 0.01 56.0 14.2 49.3 17.5 ns
Data are presented as mean and standard deviation. Ca2+ — total calcium; HF — heart failure; ns — non-significant; P — phosphorus; PTH — parathyroid hormone; 
SD — standard deviation; SE ( > / < ) 7 h/week — sun exposure “above/below” seven hours per week; vit. D — vitamin D
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(HGB) showed a trend towards statistical significance 
(r = –0.21, P = 0.093). All values are presented in Table III.
The multiple regression analysis with PTH as 
a dependent variable enabled the construction of 
a primary model, which consisted of subsequent ar-
bitrarily included parameters: age, LVEF, eGFR and 
serum blood concentrations of vitamin D, phosphorus, 
and NT-proBNP. Further calculations according to the 
backward stepwise method led to the construction of 
the secondary model, which included age, phosphorus, 
and NT-proBNP serum blood concentrations. P values 
were 0.004, 0.012, and 0.022, respectively. All data are 
presented in Table IV.
Discussion
According to our best knowledge the issue concerning 
the dependency between serum PTH concentration in 
HF patients of non-ischaemic origin and sun exposure 
in comparison to non-HF volunteers has not been elu-
cidated. The data considering vitamin D and PTH con-
centration in the Caucasian population of HF patients 
living in Central Europe remain scarce and unclear. PTH 
is not routinely evaluated in HF patients, although it 
may be a potentially important factor in the pathogen-
esis of HF and is an important clinical factor in anticipat-
ing worse prognosis of the disease [6, 7]. It is proposed 
that maintaining proper PTH serum blood concentra-
tion, by normalising serum Ca2+ and vitamin D con-
centrations, effective treatment of CKD, or potentially 
usage of calcimimetics, may play a positive role in HF 
patients treatment and decision-making processes [8]. 
Elevation of serum PTH is induced by several mecha-
nisms, such as activation of the renin-angiotensin-
aldosterone system (RAAS), which results in an increase 
in renal Ca2+ ion depletion, a high rate of diuretic intake 
in this group of patients, progressive renal degeneration 
due to chronic hypoperfusion resulting in excessive 
PTH retention, and vitamin D deficiency due to a de-
crease in physical activity with a subsequent decrease in 
sun exposure and induction of PTH secretion [9]. Serum 
PTH concentration is increased by neurohormonal sys-
tem activation, which primarily plays a compensatory 
role in the early stage of HF; however, subsequently, it 
has a growing decompensating impact on the course of 
the disease [10]. Myocardial cells express PTH-specific 
receptors, whose stimulation might be responsible for 
hypertrophy, apoptosis, and fibrosis, which is directly 
induced by either the activation of protein kinases A 
and C or arterial hypertension [11]. Numerous biologi-
cal processes are considered to be crucial in improving 
or worsening HF [12, 13]. It is widely speculated that 
elevated PTH contributes to augmentation of catabolic 
cellular activity and oxidative stress. Pilz et al. proved 
the impact of increased PTH for cardio-vascular and 
overall mortality in a large cohort of patients referred 
to coronary angiography [14]. The hazard ratio (HR) 
for occurrence of death during a nearly eight-year 
follow-up period between the third and fourth PTH 
quartiles was 1.85 for sudden cardiac death and 1.94 for 
HF cause. Pro-atherosclerotic impact of PTH, although 
often hypothesised, remains not fully elucidated. 
Despite the fact that LURIC study investigators failed 
to assess a clear link between PTH and angiographic 
Table III. Spearman correlation coefficients between 
parathyroid hormone and subsequent values in the heart 
failure group
Tabela III. Współczynniki korelacji Spearmana pomiędzy 
parathormonem i kolejnymi wartościami u pacjentów 
w grupie z niewydolnością serca
HF (n = 65)
Parameter Mean  
(interquartile range)
Spearman r P
Age (years) 51.6 (42–60) 0.26 0.035
Ca2+ [mg/dL] 9.6 (9.15–9.95) –0.29 0.020
P [mmol/L] 1.2 (0.99–1.38) –0.35 0.004
Vitamin D [ng/mL] 23.4 (13.9–32.6) –0.18 0.15
eGFR [mL/min/1.73 m2] 86.4 (68.34–104.22) –0.36 0.003
Creatinine [mg/dL] 0.7 (0.79–1.15) 0.26 0.037
AST [IU/L] 27.5 (20–31) 0.32 0.009
NT-proBNP, pg/mL 2725.0 (343–2817) 0.37 0.003
Haemoglobin [g/dL] 14.1 (12.9–15.4) –0.21 0.093
LVEF (%) 25 (16–30) –0.34 0.7
Data are presented as mean with interquartile range. AST — aspartate 
transaminase; Ca2+ — total calcium; eGFR — estimated glomerular filtration 
rate; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal pro-
brain natriuretic peptide; P — phosphorus 
Table IV. Multiple regression analysis (backward stepwise 
method) with parathyroid hormone as a dependent variable 
in heart failure patients
Tabela IV. Analiza regresji wielorakiej metodą krokową 
wsteczną z parathormonem jako zmienną zależną u chorych 
z niewydolnością serca
Primary model Secondary model
Parameter B P B P
Age (years) 1.037 0.044 1.24 0.004
LVEF (%) 0.285 0.642 – –
Vitamin D [ng/mL] –0.240 0.571 – –
P [mmol/L] –54.186 0.030 –59.56 0.012
eGFR [mL/min/1.73 m2] –0.165 0.577 – –
NT-proBNP [pg/mL] 0.002 0.105 0.003 0.022
eGFR — estimated glomerular filtration rate; LVEF — left ventricular ejection 
fraction; NT-proBNP — N-terminal pro-brain natriuretic peptide; P — phosphorus
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stage of coronary heart disease (CAD), they assumed 
the association between NT-proBNP, NYHA class, and 
PTH being an independent predictor of hospitalisation 
for heart failure [15]. This was consistent also with our 
study in which we found the relation between PTH 
and age, NT-proBNP, and phosphorus serum blood 
concentrations. CAD as a cause of HF was in these cases 
meticulously excluded by the coronary angiography 
without significant lesions performed within twelve 
months prior to the examination. PTH concentration 
could have been affected by a high intake percentage of 
diuretics and angiotensin-converting enzyme inhibitors 
(ACE-I) (88% and 100% of patients, respectively), as well 
as by the occurrence rate of CKD in the third stage with 
eGFR < 60 (mL/min/1.73 m2) in 14% of the patients. It 
is worth mentioning that in the publication of Schier-
beck et al. the percentage of diuretics and ACE-I intake 
were similar and varied between 76–97% and 57–81%, 
respectively, in patients divided into quartiles according 
to PTH serum concentration [16]. Moreover, investiga-
tors found a positive correlation of PTH with age, NT-
proBNP, and alkaline phosphatase – Pearson correlation 
coefficients were 0.233, 0.365, and 0.322 (P = 0.004, 
P < 0.001, and P < 0.001), respectively, and were co-
herent with our results. Reported negative correlation 
of PTH with ionised calcium (–0.354, P < 0.001), eGFR 
(–0.487, P < 0.001), and haemoglobin (–0.208, P = 0.01) 
support our findings, which are similar although per-
formed in a different group of patients hospitalised due 
to HF. Correlation between PTH and increased risk ratio 
of cardiovascular death in elderly males and risk of heart 
failure occurrence in the population of all patients was 
demonstrated by Hagstrom et al. [17]. Although there 
have been several studies denying the role of PTH as 
a factor correlating with the occurrence of cardiovascu-
lar disease [18, 19], in the vast majority of publications 
PTH is recognised as a predictor of hospitalisation due 
to HF decompensation and cardiovascular, as well as 
all-cause mortality [5, 14, 16, 20]. The investigation of 
Gruson et al. revealed that the serum concentration of 
bioactive PTH in hospitalised HF patients, as assessed 
using the third-generation test, was elevated in com-
parison to healthy volunteers and was correlated with 
NYHA class and neurohormonal activation, which was 
also present in our study [21]. Interestingly, this depend-
ency characterised predominantly ischaemic compared 
to non-ischaemic HF patients. The relationship between 
PTH concentration and the severity of HF in 150 con-
secutive patients with HF treated in the outpatient clinic 
shown by Altay et al. was also consistent with our find-
ings [22]. The study of Sugimoto et al. showed that low-
normal serum PTH concentration on admission was 
related to the increased incidence of in-hospital mortal-
ity due to acute decompensated heart failure compared 
to high PTH values (23.1 vs. 11.4, P = 0.013) [23]. Since 
the deceased patients had significantly higher inci-
dence of diabetes and lower incidence of dyslipidaemia 
(P = 0.03 and P = 0.045, respectively) they probably rep-
resented the group of patients with initially increased 
risk of not only short- but also long-term mortality. 
It was reported that impaired secretion of PTH within 
the physiologic range has a negative impact on contrac-
tility of cardiomyocytes [24]. Moreover, the activation 
of the adrenergic nervous system expressed by the el-
evation of serum catecholamines results in intracellular 
calcium overloading and augmentation of oxidative 
stress. These discrepancies in PTH serum concentra-
tions can be largely explained by the initially different 
clinical course of acute and chronic heart failure. Polat 
et al. demonstrated the relationship between 25OHD3 
and the echocardiographic findings connected with the 
negative LV remodelling [25]. We evaluated the possi-
ble correlation between PTH and LVEF, which turned 
out to be statistically insignificant. It might have been 
caused by the relatively wide interquartile range of 
LVEF assessments (16–30%) as well as by a frequently 
observed incoherence between the clinical status and 
LVEF examination. Serum blood concentrations of 
vitamin D in HF patients of the Polat et al. study were 
24.1 ± 10.4, which was comparable to our findings 23.4 
± 13.0; however, we observed the discrepancy between 
vitamin D serum blood concentration among the con-
trol subjects which were 41.4 ± 20.9 and 28.1 ± 11.3, 
respectively. At least partially it could be explained by 
higher solar Direct Normal Irradiation (DNI) in Turkey 
in comparison to Poland (2000 vs. 1000 kWh/m2) [26]. 
Interestingly vitamin D serum blood concentrations in 
patients with HF did not vary significantly according 
to declared sun exposure (24.1 vs. 23.2 ng/mL, P = ns), 
which suggests a more complex restitution background 
of vitamin D in the HF setting. In this study, intact-PTH 
serum concentration (second-generation assessment) in 
non-ischaemic HF patients correlated with well-estab-
lished markers of unfavourable prognosis (age, NYHA 
class, eGFR, NT-proBNP, and creatinine). Moreover, the 
PTH concentration did not correlate with the vitamin D 
concentration although the prevalence of its deficit was 
significantly higher among the HF patients compared 
to the non-HF volunteers (72% vs. 56%, P = 0.046).
Limitations of the study
Certain limitations should be considered when inter-
preting the findings of our study. Firstly, the analysed 
data represents a relatively small although highly 
selected population of consecutive patients with non-
ischaemic HF. Secondly, the patients were enrolled and 
evaluated in one centre by the investigators, which 
might have generated a potential source of selection bias. 
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Conclusions
PTH concentration is significantly elevated in a Cauca-
sian population of non-ischaemic HF patients compared 
to non-HF volunteers. This elevation is correlated with 
established factors of worse prognosis of HF such as 
age, eGFR, and serum concentrations of phosphorus 
and NT-proBNP. Declared sun exposure did not affect 
the serum concentration of vitamin D in the HF group 
compared to the control group. 
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